Alkem Labs unveils Ibuprofen, Famotidine Tablets in US
Mumbai: Alkem Laboratories Ltd. today announced the launch of Ibuprofen and Famotidine Tablets (800 mg/26.6 mg) in the United States, following an approval from the United States Food and Drug Administration (USFDA).
Ibuprofen and Famotidine Tablets is AB-rated generic therapeutic equivalent version of Horizon Medicines LLC's Duexis Tablets, 800 mg/26.6 mg.
"This is the first generic approval of Duexis Tablets, 800 mg/26.6 mg by the US FDA. The launch is a subject of ongoing litigation," Alkem Labs said in a release.
Read also: Alkem labs successfully completes USFDA inspection for Taloja Bioequivalence Center
Established in 1973 and headquartered in Mumbai, Alkem is a Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.
The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets.
Read also: Alkem Labs launches epilepsy drug Perampil in India
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.